Takeda’s layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug candidate zasocitinib, for which the pharma today announced positive Phase 3 data.
Takeda Restructuring Could Push More Than 600 US Staffers Out of Jobs Read More »
The surgical navigation and robotics system is part of the company’s push to expand its share of the $15 billion cranial and spinal technologies market.
Medtronic wins FDA clearance for robot in cranial, ENT surgeries Read More »
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline.
Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline Read More »
The FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns.
Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug Read More »
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout Read More »
AbbVie’s Skyrizi appears to have stronger efficacy than Johnson & Johnson’s newly approved pill Icotyde, as well as a less frequent dosing schedule that patients could prefer, according to analysts at BMO Capital Markets.
As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge Read More »
The Insilico Medicine agreement plays into Eli Lilly’s recent AI push, anchored by a partnership last year with NVIDIA to build a supercomputer to optimize drug discovery and shorten the development timeline.
Lilly Doubles Down on Insilico’s AI Medicines, Bets Up to $2.75B Read More »
The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.
En un estudio reciente, se ha conseguido identificar un mecanismo, que era desconocido hasta ahora, por el cual los plásmidos pueden desempeñar un papel más activo en la evolución de la resistencia a los antibióticos de lo que se pensaba hasta ahora. Los plá …
Unos científicos han conseguido “domesticar”, mediante algo definible en cierto modo como “computación viviente”, una bacteria clave para el control de patógenos vegetales. El logro abre la puerta a la utilización de esta especie bacteriana como he …
Domestican una bacteria mediante computación viviente Read More »
